Asia Healthcare Blog
Exploring the intersection of investment and development, in Asia



China, HK, Macau

March 21, 2009

Pfizer shows it’s become a veteran Chinese hand

Posted By Damjan DeNoble

Pfizer has been on both the winning and the losing sides of China patent and trademark laws since 2002.  If anything, it has learned just how different a playing field China is than the rest of the world, and that access to this potentially rich pharma market has to be earned.  That’s why the announcement by Pfizer and PlaNet finance, “to conduct an in-depth research project on the health care needs of the working poor in China,” should be amusing new to many experienced China watchers for the sheer fact that it is a testament to just how ‘Chinese’ Pfizer has become.

At this point Pfizer would fit right in with local and provincial level Chinese officials soberly putting padded red envelope donations in boxes for the Sichuan relief efforts on live television, and staring intently into cameras for a few seconds before making the drop, so as to make sure that their faces were clearly caught by the upper level cadres watching the proceedings.  Even the mission statement present in the article screams “I get it.  We gotta co-operate to get some state level love.”

Pfizer’s mission in China is to meet the diverse medical needs of the country’s population through a broad portfolio of innovative medicines and partnerships with local healthcare providers, academics, and government in order to support the rapid development of the country’s healthcare system.

From the tone of it Pfizer sounds more like an NGO or a university health department than a multi-billion dollar per year, corporate giant.  (To be clear, I am not criticizing, but most vigorously applauding Pfizer’s China shrewdness – it’s not a common enough thing here in China.)

What better way to ingratiate yourself with the Chinese government than to help the country’s rural poor?I had a professor in college that used to work with Merck, and one thing she said that stuck is to always look for why pharmaceuticals do certain outreach projects.  What I found that semester is that with Asian country’s in particular, pharmaceuticals have found public health projects to be great tools in the fight for market share.

With that little piece of wisdom firmly in mind, I am interested to see what big initiative Pfizer will announce in the coming year.



About the Author

Damjan Denoble
Damjan co-founded Asia Healthcare Blog with James Flanagan, in 2009. He is currently a JD/MA dual-degree student in Law and Chinese Studies, at The University of Michigan Law School. Last summer he clerked at the offices of Harris & Moure, a boutique international law firm widely admired for its China Law Blog. He graduated from Duke University in 2007, with a B.A. in Public Policy, concentration in health policy.




One Comment


  1. Pfizer’s China Strategy shows why they are still alive in the Big Pharma Consolidation Wars «Asia Healthcare Blog

    [...] a year ago I made a post about how Pfizer had really become a veteran Chinese hand, after it had agreed to conduct a study on the needs of China's rural poor.  This was seven years [...]

    Reply
    February 3, 2010 at 6:34 pm



Leave a Reply